Clinical Trial Update: Safety, Tolerability and Effect of ARC-AAT Injection on Circulating and Intrahepatic Alpha-1 Antitrypsin Levels [Phase 2]

View source ↗

Summary

Phase 2 study ARC-AAT for Alpha-1 Antitrypsin Deficiency was withdrawn; the trial evaluated safety, tolerability, and effects on circulating and intrahepatic al…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alpha-1 Antitrypsin Deficiency

Drugs mentioned

• ARC-AAT

Snippet

Sponsor: Arrowhead Pharmaceuticals | Conditions: Alpha-1 Antitrypsin Deficiency | Phase 2 | Status: WITHDRAWN